RESUMEN
Objective To establish a double-antibody sandwich enzyme linked immunosorbent assay (DAS-ELISA) for the rapid detection of germ tube-specific antigens of Candida albicans,and to evaluate its specificity and sensitivity.Methods A DAS-ELISA was established with the monoclonal antibody McAb03.2C1-C2 as the primary antibody,and horseradish peroxidase (HRP) labeled McAb03.2C1-C2 as the secondary antibody.The established assay was used to detect germ tube-specific antigens of Candida albicans in sera from 5 patients with systemic Candida albicans infection and from 6 rabbit models at 12,24,48,72hours,on week 1,2 after infection with Candida albicans.Results A good liner relationship was observed between the absorbance value at 495 nm and antigen concentrations when the titer of McAb03.2C1-C2 was 1 ∶ 4000 and the concentration of coated antigen varied from 1.25 to 40 μg/ml.The specificity and sensitivity of the DAS-ELISA were 95％ and 92％ respectively in the detection of germ tube-specific antigens in the rabbit models.The results of detection with DAS-ELISA in serum specimens from the patients were consistent with those with the routine method.Conclusions A DAS-ELISA is primarily established for the rapid detection of germ tube-specific antigens of Candida albicans,and has shown a satisfactory sensitivity and specificity in the animal model experiment.
RESUMEN
Objective To investigate whether the sort of drugs causing drug eruptions complicated with drug-induced liver dysfunction are the same as those causing drug eruptions. Methods Sixty-one cases of drug eruption complicated with drug-induced liver dysfunction in 261 cases confirmed as drug eruptions from January 1998 to March 2003 were analyzed retrospectively. Results The major hepatotoxic drugs in these cases were antivirus drugs (60%, 9/15), antituberculosis drugs (66.67%, 8/12), zyloric (55.56%, 5/9), and some traditional Chinese medicines (31.58%, 6/19). Conclusion The sort of drugs causing drug eruptions complicated with drug-induced liver dysfunction are the same as those causing drug eruptions, which should be taken into consideration in clinical medication.